PUBLIC COMPANY
saveAlentis Therapeutics AG
updated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 5pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Rescue of Nephrons With ALE.F02 (RENAL-F02)
- phase2A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- phase2A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- phase2Study of ALE.C04 in Patients With Head and Neck Cancer
- phase1A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
🐶 Hiring Signal
News
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drugAustralia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.fiercebiotech · 9h ago
- CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drugThe Australian drugmaker CSL will pay $355 million for Alentis Therapeutics’ anti-fibrosis drug, plus as much as $1.2 billion in future payments. Under the deal announced Sunday evening, CSL will c…endpoints · 11h ago
comments(0)
5-min edit window · permanent after that